New drug aims to reactivate Cancer-Fighting genes in solid tumors
NCT ID NCT07303387
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing valemetostat, a daily pill, in 900 adults with advanced solid tumors that have specific gene changes (like SMARCB1 or ARID1A). The drug works by blocking EZH1/2 enzymes to reactivate genes that normally protect against cancer. The main goal is to see if the tumor shrinks or stops growing. Participants take the drug for up to two years and are monitored closely for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Léon Berard
NOT_YET_RECRUITINGLyon, 69373, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Gustave Roussy
RECRUITINGVillejuif, Val de Marne, 94805, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Bergonié
NOT_YET_RECRUITINGBordeaux, 33076, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Curie
NOT_YET_RECRUITINGParis, 75005, France
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Valemetostat (a drug that blocks EZH1/2 enzymes to reactivate cancer-protecting genes)
What this could lead to
If it works, this could offer a new targeted treatment option for people with certain hard-to-treat solid tumors that have specific gene changes.
What could go wrong
This is an early phase 2 trial, so it is not yet proven to work. Side effects from valemetostat are possible, and the drug may not shrink tumors or improve survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.